ArticleEClinicalMedicine2023
Deep learning-enabled fully automated pipeline system for segmentation and classification of single-mass breast lesions using contrast-enhanced mammography: a prospective, multicentre study.
Article in EClinicalMedicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- A non-invasive end-to-end intelligent assistance system for breast ultrasound.Nature communications · 2026Article
- Predictive deep learning model based on contrast-enhanced mammography for breast cancer diagnosis: a pilot study.BJR artificial intelligence · 2026Article
- Deep learning-assisted diagnosis of pubertal breast development on multicenter ultrasound images.iScience · 2025Article
- 조영증강 유방촬영술: 현재의 임상적 활용과 미래 방향에 대한 종합적 고찰.Journal of the Korean Society of Radiology · 2025Review
- From Innovation to Application: Can Emerging Imaging Techniques Transform Breast Cancer Diagnosis?Diagnostics (Basel, Switzerland) · 2025Review
- Contrast-Enhanced Mammography in Breast Lesion Assessment: Accuracy and Surgical Impact.Tomography (Ann Arbor, Mich.) · 2025Article
- Reducing the workload of medical diagnosis through artificial intelligence: A narrative review.Medicine · 2025Review
- Review
- Application of multi-feature-based machine learning models to predict neurological outcomes of cardiac arrest.Resuscitation plus · 2024Review
- Artificial Intelligence in Surgery: A Systematic Review of Use and Validation.Journal of clinical medicine · 2024Review
- Deep learning-based automatic pipeline system for predicting lateral cervical lymph node metastasis in patients with papillary thyroid carcinoma using computed tomography: A multi-center study.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2024Article
- Deep Learning in Breast Cancer Imaging: State of the Art and Recent Advancements in Early 2024.Diagnostics (Basel, Switzerland) · 2024Review
- Artificial Intelligence in Senology - Where Do We Stand and What Are the Future Horizons?European journal of breast health · 2024Article
- State-of-the-art for contrast-enhanced mammography.The British journal of radiology · 2024Review
- Contrast-enhanced mammography: better with AI?European radiology · 2024Article
- AI-Based Cancer Detection Model for Contrast-Enhanced Mammography.Bioengineering (Basel, Switzerland) · 2023Article
- Artificial Intelligence Applied to Contrast-enhanced Mammography: Exploring Uncharted Territory.Radiology · 2023Article
- Empowering breast cancer diagnosis and radiology practice: advances in artificial intelligence for contrast-enhanced mammography.Frontiers in radiology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Breast cancer is the leading cause of cancer-related deaths in women. However, accurate diagnosis of breast cancer using medical images heavily relies on the experience of radiologists. This study aimed to develop an artificial intelligence model that diagnosed single-mass breast lesions on contrast-enhanced mammography (CEM) for assisting the diagnostic workflow. Methods: A total of 1912 women with single-mass breast lesions on CEM images before biopsy or surgery were included from June 2017 to October 2022 at three centres in China. Samples were divided into training and validation sets, internal testing set, pooled external testing set, and prospective testing set. A fully automated pipeline system (FAPS) using RefineNet and the Xception + Pyramid pooling module (PPM) was developed to perform the segmentation and classification of breast lesions. The performances of six radiologists and adjustments in Breast Imaging Reporting and Data System (BI-RADS) category 4 under the FAPS-assisted strategy were explored in pooled external and prospective testing sets. The segmentation performance was assessed using the Dice similarity coefficient (DSC), and the classification was assessed using heatmaps, area under the receiver operating characteristic curve (AUC), sensitivity, and specificity. The radiologists' reading time was recorded for comparison with the FAPS. This trial is registered with China Clinical Trial Registration Centre (ChiCTR2200063444). Findings: The FAPS-based segmentation task achieved DSCs of 0.888 ± 0.101, 0.820 ± 0.148 and 0.837 ± 0.132 in the internal, pooled external and prospective testing sets, respectively. For the classification task, the FAPS achieved AUCs of 0.947 (95% confidence interval [CI]: 0.916-0.978), 0.940 (95% [CI]: 0.894-0.987) and 0.891 (95% [CI]: 0.816-0.945). It outperformed radiologists in terms of classification efficiency based on single lesions (6 s vs 3 min). Moreover, the FAPS-assisted strategy improved the performance of radiologists. BI-RADS category 4 in 12.4% and 13.3% of patients was adjusted in two testing sets with the assistance of FAPS, which may play an important guiding role in the selection of clinical management strategies. Interpretation: The FAPS based on CEM demonstrated the potential for the segmentation and classification of breast lesions, and had good generalisation ability and clinical applicability. Funding: This study was supported by the Taishan Scholar Foundation of Shandong Province of China (tsqn202211378), National Natural Science Foundation of China (82001775), Natural Science Foundation of Shandong Province of China (ZR2021MH120), and Special Fund for Breast Disease Research of Shandong Medical Association (YXH2021ZX055).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.